The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Evolution: Phase II study of radionuclide 177Lu-PSMA-617 therapy versus 177Lu-PSMA-617 in combination with ipilimumab and nivolumab for men with metastatic castration-resistant prostate cancer (mCRPC; ANZUP 2001).
 
Shahneen Sandhu
Honoraria - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Merck (Inst)
Consulting or Advisory Role - Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb/Roche (Inst); Genentech (Inst); Merck Sharp and Dohme (Inst); Novartis (Inst)
Speakers' Bureau - AstraZeneca (Inst); Bristol-Myers Squibb; Merck; Roche/Genentech
Research Funding - Amgen (Inst); AstraZeneca (Inst); Endocyte/Advanced Accelerator Applications (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Senhwa Biosciences (Inst)
(OPTIONAL) Uncompensated Relationships - AAA/Endocyte/Novartis (Inst)
 
Shalini Subramaniam
No Relationships to Disclose
 
Michael S Hofman
Consulting or Advisory Role - Endocyte; Janssen; POINT Biopharma
Speakers' Bureau - Astellas Pharma; AstraZeneca; Janssen; Mundipharma
Research Funding - Advanced Accelerator Applications/Novartis (Inst); Bayer (Inst); Endocyte (Inst)
Travel, Accommodations, Expenses - Genzyme; Ipsen; Janssen
 
Martin R. Stockler
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bionomics (Inst); Bristol-Myers Squibb (Inst); Medivation (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Tilray (Inst)
Travel, Accommodations, Expenses - Medivation/Pfizer
 
Andrew James Martin
No Relationships to Disclose
 
Izabella Pokorski
No Relationships to Disclose
 
Jeffrey C. Goh
Stock and Other Ownership Interests - Icon Cancer Center; Immutep
Honoraria - AstraZeneca; Ipsen; Janssen; MSD/Merck; Mundipharma
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Eisai; GlaxoSmithKline
Speakers' Bureau - GlaxoSmithKline; Ipsen; MSD
Research Funding - BeiGene (Inst)
 
David A. Pattison
Honoraria - Ipsen
Travel, Accommodations, Expenses - Eisai
 
Nattakorn Dhiantravan
No Relationships to Disclose
 
Craig Gedye
No Relationships to Disclose
 
Natalie K. Rutherford
No Relationships to Disclose
 
Anthony M. Joshua
Stock and Other Ownership Interests - Pricilium Therapeutics
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); IDEAYA Biosciences (Inst); Ipsen (Inst); IQvia (Inst); Janssen Oncology (Inst); Merck Serono (Inst); Neoleukin Therapeutics (Inst); Novartis (Inst); Noxopharm (Inst); Pfizer (Inst); Sanofi (Inst)
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Janssen Oncology (Inst); Lilly (Inst); Lilly (Inst); Macrogenics (Inst); Mayne Pharma (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Cancer therapeutic methods
 
Thean Hsiang Tan
Speakers' Bureau - Ipsen; Janssen Oncology
 
Ian D. Kirkwood
Stock and Other Ownership Interests - Alcidion; CSL Limited; ResMed; Sonic Healthcare
Research Funding - Bayer (Inst); Clarity Pharmaceuticals (Inst); Fusion Pharmaceuticals (Inst); ImaginAb (Inst); Provectus (Inst)
 
Sze Ting Lee
No Relationships to Disclose
 
Andrew James Weickhardt
Honoraria - Eisai; Merck Sharp & Dohme
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Sharp & Dohme; Pfizer
Speakers' Bureau - Astellas Pharma
Research Funding - Merck
Travel, Accommodations, Expenses - Astellas Pharma; Ipsen; Merck Sharp & Dohme
 
Ramin Alipour
No Relationships to Disclose
 
Andrew Nguyen
No Relationships to Disclose
 
Ian D. Davis
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Ipsen (Inst); Janssen Oncology (Inst); Medivation (Inst); Movember Foundation (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst)
Patents, Royalties, Other Intellectual Property - International Patent Application No: PCT /US2004/032147 (NY-ESO-1) through Ludwig Institute for Cancer Research.
 
Louise Emmett
Honoraria - Astellas Pharma; AstraZeneca; Janssen Oncology; Mundipharma; Telix Pharmaceuticals
Consulting or Advisory Role - Noxopharm
Speakers' Bureau - Janssen Oncology; Janssen Oncology; mundipharma
Research Funding - Novartis (Inst); Novartis (Inst); Noxopharm (Inst); Noxopharm (Inst)